Merck acquires HUB Organoids Holding B.V.
17/12/2024 - Merck, a global leader in science and technology, announced a definitive agreement to acquire HUB Organoids Holding B.V. (HUB), a Dutch company recognized internationally as a pioneer in organoid development. Organoids are innovative 3D cell culture models that mimic the functionality of human organs, offering transformative potential in drug development, disease research, and reduction of animal testing.
Based in Utrecht, Netherlands, HUB employs approximately 70 specialists and holds foundational patents in organoid technology. Financial details of the transaction have not been disclosed, but the acquisition is expected to close by the end of December 2024.
Advancing Drug Development Through Next-Generation Biology
“HUB’s expertise in organoid technology strengthens Merck’s portfolio and underscores our commitment to next-generation biology,” said Jean-Charles Wirth, Head of Science & Lab Solutions for Merck Life Science. “Organoids offer unparalleled insights into biological systems, accelerating breakthroughs in drug development and disease understanding. Together, we aim to empower researchers with faster, more effective solutions from samples to discoveries.”
HUB’s technology portfolio enables drug developers to identify and validate clinical candidates in a patient-relevant, in vitro system. Its services span model generation, assay development, and high-throughput screening, complementing Merck’s offerings in 2D and 3D cell culture tools, reagents, and instruments.
Driving Sustainability and Diversity in Research
The integration of organoids into research processes supports Merck’s sustainability and inclusion goals. By reducing reliance on animal testing, organoids contribute to environmentally sustainable alternatives in R&D. Additionally, these models enable researchers to study drug interactions in diverse populations, addressing gaps in underrepresented patient groups during clinical trials.
Robert Vries, CEO of HUB Organoids, emphasized the strategic alignment: “Merck’s resources and reach provide a multiplier effect for our proprietary technology, allowing us to expand our impact with customers and, ultimately, improve outcomes for patients.”
Tapping into a Rapidly Growing Market
The acquisition positions Merck at the forefront of the burgeoning 3D cell culture market, anticipated to grow at double-digit rates annually over the next decade. Merck’s established portfolio includes tumor spheroids, stem cell organoids, and 3D bioprinting technologies, complemented by advanced downstream analysis tools and reagents.
About Merck
Merck operates across life sciences, healthcare, and electronics, with approximately 63,000 employees in 65 countries. Known for its commitment to scientific innovation since 1668, the company generated €21 billion in sales in 2023.
About HUB Organoids Holding B.V.
HUB is a global leader in adult stem cell-derived organoids, offering proprietary technology and services to advance drug discovery, personalized medicine, and regenerative therapies.
This acquisition marks a significant milestone in the advancement of 3D cell culture technologies, promising new efficiencies and insights in medical research and drug development.